A Look At LifeStance Health Group (LFST) Valuation After Recent Share Price Momentum And Earnings Expectations

Stock performance snapshot and recent context LifeStance Health Group (LFST) has drawn attention after a recent move in its share price, with the stock last closing at US$7.65 and showing mixed short term returns alongside stronger figures over the past year. See our latest analysis for LifeStance Health Group. Recent trading has cooled slightly, with the 1-day share price return down 3.04% and the 7-day share price return down 0.65%. However, the 30-day share price return of 14.69% and 1-year total shareholder return of 30.99% point to momentum that has been building over a longer stretch despite a softer 3-year total shareholder return. If you are comparing LifeStance Health Group with other healthcare opportunities, this is a good moment to see what else is moving in mental health tech and related areas through 32 healthcare AI stocks With LifeStance Health Group showing rising annual revenue and net income alongside a strong 1-year return, yet trading about 40% below the average analyst price target, is this a genuine opening, or is the market already pricing in future growth? Most Popular Narrative: 15% Undervalued With LifeStance Health Group’s most followed narrative pointing to a fair value around $9.00 against a last close of $7.65, the gap centers on how confidently future earnings and margins can compound over time. Investments in AI and digital technology platforms (such as automated revenue cycle tools, patient engagement systems, and enhanced care matching) are expected to drive operating leverage, reduce administrative costs, and improve clinician productivity, resulting in higher net margins and increased earnings longer term. Read the complete narrative. Want to see why this narrative still supports a higher valuation even after trimming growth and profit assumptions? The entire case leans on earnings climbing faster than revenue and a future earnings multiple more commonly associated with fast growing healthcare platforms. Curious which specific margin targets and growth runway have been baked into that $9.00 outcome and how a higher future P/E is justified over today’s level? The full narrative lays out the exact earnings path and valuation bridge that links today’s $7.65 price to that fair value mark. Result: Fair Value of $9 (UNDERVALUED) Have a read of the narrative in full and understand what's behind the forecasts. However, this upside story could unravel if reimbursement pressure tightens or if clinician recruitment and retention issues begin to cap visit growth and profitability. Find out about the key risks to this LifeStance Health Group narrative. Another angle on valuation That $9.00 fair value is built on future earnings, but the current P/E of about 127.9x tells a different story. This stands out when compared with the US Healthcare sector at 22.4x, peers at 54.8x, and even the 49.5x fair ratio. Is the stock already pricing in too much? See what the numbers say about this price — find out in our valuation breakdown. NasdaqGS:LFST P/E Ratio as at May 2026Next Steps The mix of potential upside and clear risks here is hard to ignore, so move quickly, review the underlying data, and decide where you stand with 3 key rewards and 1 important warning sign Looking for more investment ideas? If LifeStance has sharpened your focus, do not stop here. Broaden your watchlist with other stocks that match clear, disciplined criteria using the Simply Wall St screener. Target companies that combine quality and attractive pricing by scanning a focused list of 51 high quality undervalued stocks. Prioritise resilience by reviewing 66 resilient stocks with low risk scores that score well on stability and downside protection. Spot potential early movers before the crowd by checking the screener containing 21 high quality undiscovered gems hiding strong fundamentals. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.New: AI Stock Screener & AlertsOur new AI Stock Screener scans the market every day to uncover opportunities.• Dividend Powerhouses (3%+ Yield)• Undervalued Small Caps with Insider Buying• High growth Tech and AI CompaniesOr build your own from over 50 metrics.Explore Now for Free